AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17557688 — intervention group
Group type: EXPERIMENTAL
Intervention: Coloured overlay
Number of subjects: 0
Study 17557688 — intervention group
Group type: COMPARATOR
Intervention: Reading-age controls
Number of subjects: 0
Study 16480346 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal tube
Number of subjects: 0
Study 16480346 — intervention group
Group type: COMPARATOR
Intervention: Laryngeal mask airway
Number of subjects: 0
Study 15333452 — intervention group
Group type: COMPARATOR
Intervention: Oral lactobacillus
Number of subjects: 278
Study 15333452 — intervention group
Group type: COMPARATOR
Intervention: Vaginal lactobacillus
Number of subjects: 278
Study 15333452 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 278
Study 11523750 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-directed program consisting of booklets and follow-up calls by health educators
Number of subjects: 0
Study 11523750 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 0
Study 8880290 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lysine clonixinate 4 mg x kg‐1
Number of subjects: 10
Study 8880290 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lysine clonixinate 6 mg x kg‐1
Number of subjects: 10
Study 2059818 — intervention group
Group type: EXPERIMENTAL
Intervention: Duplex ultrasonography
Number of subjects: 65
Study 6881687 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol aerosol delivered by the patients' own technique
Number of subjects: 13
Study 6881687 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol aerosol delivered under supervision by a trained member of staff
Number of subjects: 13
Study 6881687 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol aerosol delivered with a spacer device (Aerochamber)
Number of subjects: 13
Study 6881687 — intervention group
Group type: COMPARATOR
Intervention: Placebo aerosol
Number of subjects: 13
Study 30202916 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily tobacco consumption (10 g/day increase)
Number of subjects: 103557
Study 30202916 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative tobacco consumption (10 pack-years increase)
Number of subjects: 103557
Study 30202916 — intervention group
Group type: EXPERIMENTAL
Intervention: CHRNA3 rs1051730 genotype (proxy for tobacco consumption)
Number of subjects: 103557
Study 31143771 — intervention group
Group type: EXPERIMENTAL
Intervention: 635 nm laser (G1)
Number of subjects: 24
Study 31143771 — intervention group
Group type: COMPARATOR
Intervention: Control (G2)
Number of subjects: 24
Study 28477944 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein diet (1.7 g/kg per day) during hospitalization, daily protein supplement (18.8 g), and 3 weekly resistance training sessions for 12 weeks after discharge
Number of subjects: 29
Study 28477944 — intervention group
Group type: COMPARATOR
Intervention: Standard-care
Number of subjects: 29
Study 28477944 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein diet and resistance training
Number of subjects: 29
Study 25391814 — intervention group
Group type: EXPERIMENTAL
Intervention: Psyllium (7.0 g daily)
Number of subjects: 51
Study 25391814 — intervention group
Group type: COMPARATOR
Intervention: Cellulose (equivalent amount to psyllium)
Number of subjects: 51
Study 23390204 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening arm (intervention)
Number of subjects: 0
Study 23390204 — intervention group
Group type: COMPARATOR
Intervention: Control arm (control)
Number of subjects: 0
Study 21664880 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 30
Study 21664880 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 18641424 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention (face-to-face education and group seminar in public hospitals; face-to-face education only in private hospitals)
Number of subjects: 40
Study 18641424 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention (group seminar)
Number of subjects: 40
Study 18641424 — intervention group
Group type: COMPARATOR
Intervention: Control (face-to-face education only in private hospitals)
Number of subjects: 40
Study 16636130 — intervention group
Group type: EXPERIMENTAL
Intervention: r‐metHuLeptin therapy
Number of subjects: 7
Study 16636130 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 12801313 — intervention group
Group type: EXPERIMENTAL
Intervention: montelukast 10 mg/desloratadine 5 mg combination
Number of subjects: 15
Study 12801313 — intervention group
Group type: EXPERIMENTAL
Intervention: montelukast 10 mg alone
Number of subjects: 15
Study 12801313 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 15
Study 12801313 — intervention group
Group type: EXPERIMENTAL
Intervention: montelukast/desloratadine
Number of subjects: 15
Study 12801313 — intervention group
Group type: EXPERIMENTAL
Intervention: montelukast
Number of subjects: 15
Study 10824413 — intervention group
Group type: EXPERIMENTAL
Intervention: Lyophilized Enterococcus faecium M‐74 in the form of waffles (Dr. Ebi)
Number of subjects: 0
Study 10824413 — intervention group
Group type: COMPARATOR
Intervention: Placebo (waffles without active ingredient)
Number of subjects: 0
Study 8852914 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral acyclovir therapy (300 mg/m2/dose, administered either twice daily or three times per day for 6 months)
Number of subjects: 26
Study 8852914 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral acyclovir therapy
Number of subjects: 26
Study 1497125 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl (5 micrograms/kg bolus, 2 micrograms kg‐1 h‐1 infusion)
Number of subjects: 60
Study 1497125 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentazocine (2 mg/kg bolus, 0.8 mg kg‐1 h‐1 infusion)
Number of subjects: 60
Study 1497125 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (2 mg/kg bolus, 0.8 mg kg‐1 h‐1 infusion)
Number of subjects: 60
Study 1497125 — intervention group
Group type: EXPERIMENTAL
Intervention: Enflurane (0.5‐2 vol.% added if insufficient anaesthesia)
Number of subjects: 60
Study 1497125 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-operative recovery and pain monitored using verbal rating scales
Number of subjects: 60
Study 6140128 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg tiapride 3-times daily for 14 days
Number of subjects: 42
Study 6140128 — intervention group
Group type: COMPARATOR
Intervention: 200 mg glafenine 3-times daily for 14 days
Number of subjects: 42
Study 30854728 — intervention group
Group type: COMPARATOR
Intervention: Transcranial direct current stimulation (tDCS) applied to primary sensory-motor hand regions (anode left, cathode right)
Number of subjects: 15
Study 30854728 — intervention group
Group type: COMPARATOR
Intervention: Transcranial direct current stimulation (tDCS)
Number of subjects: 15
Study 27916737 — intervention group
Group type: EXPERIMENTAL
Intervention: SSB+SCB (n=30): 15mL of bupivacaine 0.25% for SSB and 15mL of bupivacaine 0.25% for SCB
Number of subjects: 60
Study 27916737 — intervention group
Group type: COMPARATOR
Intervention: ISB (n=30): 30mL of bupivacaine 0.25%
Number of subjects: 60
Study 27326239 — intervention group
Group type: COMPARATOR
Intervention: Riociguat (maximum 2.5 mg three times daily or 1.5 mg three times daily in PATENT‐1; maximum 2.5 mg three times daily in CHEST‐1)
Number of subjects: 109
Study 27326239 — intervention group
Group type: COMPARATOR
Intervention: Riociguat
Number of subjects: 109
Study 25059727 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracuff pressure of 60 cm H2 O
Number of subjects: 36
Study 25059727 — intervention group
Group type: COMPARATOR
Intervention: Intracuff pressure of 40 cm H2 O
Number of subjects: 36
Study 25059727 — intervention group
Group type: COMPARATOR
Intervention: Intracuff pressure of 80 cm H2 O
Number of subjects: 36
Study 22433921 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole (RPZ) 20 mg b.i.d.
Number of subjects: 337
Study 22433921 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole (RPZ) 10 mg b.i.d.
Number of subjects: 337
Study 22433921 — intervention group
Group type: COMPARATOR
Intervention: Rabeprazole (RPZ) 20 mg q.d. (control)
Number of subjects: 337
Study 19505390 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized flunisolide (40 microg/kg twice daily for 7 days, then 20 microg/kg twice daily for 14 days)
Number of subjects: 46
Study 19505390 — intervention group
Group type: COMPARATOR
Intervention: Nebulized budesonide (0.5 mg twice daily for 7 days, then 0.25 mg twice daily for 15 days)
Number of subjects: 46
Study 17440205 — intervention group
Group type: EXPERIMENTAL
Intervention: Induced anger
Number of subjects: 3
Study 15893621 — intervention group
Group type: COMPARATOR
Intervention: Td vaccine
Number of subjects: 323
Study 15893621 — intervention group
Group type: EXPERIMENTAL
Intervention: TdaP vaccine
Number of subjects: 323
Study 15893621 — intervention group
Group type: EXPERIMENTAL
Intervention: TdaP-IPV (Aventis Pasteur)
Number of subjects: 323
Study 15893621 — intervention group
Group type: EXPERIMENTAL
Intervention: TdaP (GlaxoSmithKline)
Number of subjects: 323
Study 11682426 — intervention group
Group type: EXPERIMENTAL
Intervention: Inflatable pillows (Shoulder‐Float) beneath the chest wall and head
Number of subjects: 15
Study 11682426 — intervention group
Group type: COMPARATOR
Intervention: Gel-pad
Number of subjects: 15
Study 11682426 — intervention group
Group type: COMPARATOR
Intervention: 1000-mL lactated Ringer's bag
Number of subjects: 15
Study 9458425 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 71
Study 9458425 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study 7936893 — intervention group
Group type: EXPERIMENTAL
Intervention: Bundled infants (n = 36)
Number of subjects: 64
Study 7936893 — intervention group
Group type: COMPARATOR
Intervention: Control infants (n = 28)
Number of subjects: 64
Study 7936893 — intervention group
Group type: COMPARATOR
Intervention: Comparison of bundled infants to nonbundled controls
Number of subjects: 64
Study 3154312 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 63
Study 3154312 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine
Number of subjects: 63
Study 3154312 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiapamil
Number of subjects: 63
Study 3154312 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 63
Study 30340917 — intervention group
Group type: EXPERIMENTAL
Intervention: Allostatic load (AL) measured at baseline
Number of subjects: 106
Study 29134964 — intervention group
Group type: EXPERIMENTAL
Intervention: High Definition (HD) colonoscopy
Number of subjects: 270
Study 29134964 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Chromoendoscopy (VCE)
Number of subjects: 270
Study 29134964 — intervention group
Group type: COMPARATOR
Intervention: Dye Spraying Chromoendoscopy (DCE)
Number of subjects: 270
Study 27314584 — intervention group
Group type: EXPERIMENTAL
Intervention: Full interactive pre-MRI instruction (n=64)
Number of subjects: 121
Study 27314584 — intervention group
Group type: COMPARATOR
Intervention: Partial instruction (n=57)
Number of subjects: 121
Study 25607740 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh RBCs (7-15 days storage)
Number of subjects: 128
Study 25607740 — intervention group
Group type: EXPERIMENTAL
Intervention: RBCs (25-38 days storage)
Number of subjects: 128
Study 25607740 — intervention group
Group type: EXPERIMENTAL
Intervention: RBCs (16-24 days storage)
Number of subjects: 128
Study 25607740 — intervention group
Group type: EXPERIMENTAL
Intervention: Washed RBCs (> 27 days storage)
Number of subjects: 128
Study 25607740 — intervention group
Group type: COMPARATOR
Intervention: Unwashed RBCs
Number of subjects: 128
Study 24090294 — intervention group
Group type: EXPERIMENTAL
Intervention: Audiovisual distraction
Number of subjects: 84
Study 24090294 — intervention group
Group type: COMPARATOR
Intervention: Control group (no audiovisual distraction)
Number of subjects: 84
Study 20664121 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated 'positive' study (showing adverse fetal effects)
Number of subjects: 0
Study 20664121 — intervention group
Group type: COMPARATOR
Intervention: Simulated 'negative' study (showing no adverse fetal effects)
Number of subjects: 0
Study 18258628 — intervention group
Group type: EXPERIMENTAL
Intervention: Brazil nuts
Number of subjects: 59
Study 18258628 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenomethionine
Number of subjects: 59
Study 18258628 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 17021319 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.3 mg
Number of subjects: 423
Study 17021319 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 mg
Number of subjects: 423
Study 17021319 — intervention group
Group type: COMPARATOR
Intervention: Verteporfin
Number of subjects: 423
Study 12748510 — intervention group
Group type: EXPERIMENTAL
Intervention: Docosahexaenoic acid supplementation (approximately 200 mg/d)
Number of subjects: 0
Study 12748510 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10807815 — intervention group
Group type: EXPERIMENTAL
Intervention: MDI with Nebuchamber (placebo MDI through NESD, four puffs) and salbutamol 0.5 mL (2.5 mg) as NWA (group I, n = 19)
Number of subjects: 42
Study 10807815 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol MDI and 0.5 mL of saline solution (group II, n = 23)
Number of subjects: 42
Study 10807815 — intervention group
Group type: EXPERIMENTAL
Intervention: MDI with Nebuchamber (group I)
Number of subjects: 42
Study 10807815 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol MDI (group II)
Number of subjects: 42
Study 10807815 — intervention group
Group type: COMPARATOR
Intervention: MDI with NESD
Number of subjects: 42
Study 10807815 — intervention group
Group type: COMPARATOR
Intervention: NWA
Number of subjects: 42
Study 9298122 — intervention group
Group type: COMPARATOR
Intervention: Moisturizer applied before immersion (prevention study)
Number of subjects: 12
Study 9298122 — intervention group
Group type: COMPARATOR
Intervention: Moisturizer applied after immersion (therapeutic study)
Number of subjects: 12
Study 8117556 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical treatment with mucopolysaccharide polysulphate/salicylic acid cream
Number of subjects: 156
Study 8117556 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 156
Study 3571545 — intervention group
Group type: EXPERIMENTAL
Intervention: Drionic unit
Number of subjects: 22
Study 30607719 — intervention group
Group type: EXPERIMENTAL
Intervention: Photobiomodulation therapy (PBMT) 300 J per thigh
Number of subjects: 12
Study 28694341 — intervention group
Group type: EXPERIMENTAL
Intervention: Open reduction and internal fixation with locking plate
Number of subjects: 80
Study 28694341 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment with functional bracing
Number of subjects: 80
Study 26364533 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot reflexology massage (once a day for three days)
Number of subjects: 70
Study 23658147 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention Modification Program (AMP)
Number of subjects: 42
Study 23658147 — intervention group
Group type: COMPARATOR
Intervention: Attention Control Condition (ACC)
Number of subjects: 42
Study 21677618 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 7
Study 19808491 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency catheter ablation (RFA) with/without antiarrhythmic drug (AAD)
Number of subjects: 100
Study 19808491 — intervention group
Group type: COMPARATOR
Intervention: Antiarrhythmic drug (AAD) alone
Number of subjects: 100
Study 17909123 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 104
Study 17909123 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 104
Study 17909123 — intervention group
Group type: COMPARATOR
Intervention: Healthy control group
Number of subjects: 104
Study 17909123 — intervention group
Group type: EXPERIMENTAL
Intervention: First-episode schizophrenia group
Number of subjects: 104
Study 15801502 — intervention group
Group type: EXPERIMENTAL
Intervention: Common speed treadmill run at 10.5 km x h(‐1) (absolute intensity)
Number of subjects: 20
Study 15801502 — intervention group
Group type: COMPARATOR
Intervention: Relative exercise intensity trial at 65% of VO2max
Number of subjects: 20
Study 11194244 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin aspart
Number of subjects: 29
Study 11194244 — intervention group
Group type: COMPARATOR
Intervention: Buffered regular human insulin
Number of subjects: 29
Study 9891194 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloral hydrate (CH) alone (70 mg/kg)
Number of subjects: 40
Study 9891194 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloral hydrate/hydroxyzine (CH/H) (70 mg/kg CH + 2 mg/kg hydroxyzine)
Number of subjects: 40
Study 9891194 — intervention group
Group type: COMPARATOR
Intervention: Control group (Chloral hydrate alone)
Number of subjects: 40
Study 8015507 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg/24 h administration of oestradiol valerate
Number of subjects: 63
Study 8015507 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mg/day of percutaneous 17 beta-oestradiol
Number of subjects: 63
Study 8015507 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05 mg/day of transdermic oestradiol
Number of subjects: 63
Study 2660632 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketotifen syrup
Number of subjects: 284
Study 2660632 — intervention group
Group type: COMPARATOR
Intervention: Clemastine syrup
Number of subjects: 284
Study 19938055 — intervention group
Group type: EXPERIMENTAL
Intervention: iPod 3G, iPod Photo, and iPod Touch with telemetry communication
Number of subjects: 54
Study 19938055 — intervention group
Group type: EXPERIMENTAL
Intervention: iPod 3G, iPod Photo, and iPod Touch without telemetry communication
Number of subjects: 54
Study 354474 — intervention group
Group type: EXPERIMENTAL
Intervention: 265 mg theophylline (150 mg slow-release)
Number of subjects: 12
Study 354474 — intervention group
Group type: EXPERIMENTAL
Intervention: 265 mg theophylline + 7.5 mg hydroxyzine hydrochloride
Number of subjects: 12
Study 354474 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 31830776 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy plus probiotics (group B)
Number of subjects: 183
Study 31830776 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy plus sulforaphane (group C)
Number of subjects: 183
Study 31830776 — intervention group
Group type: COMPARATOR
Intervention: Triple therapy only (group A)
Number of subjects: 183
Study 31306386 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 100
Study 31306386 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 100
Study 28443690 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 days of vaginal micronised progesterone tablets (Group A)
Number of subjects: 303
Study 28443690 — intervention group
Group type: COMPARATOR
Intervention: 5 days of vaginal micronised progesterone (Group B)
Number of subjects: 303
Study 25818061 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion, sustained-release 150 mg, twice daily
Number of subjects: 204
Study 25818061 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 204
Study 23963057 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine (ATX) 0.5-1.8 mg/kg per day
Number of subjects: 398
Study 23963057 — intervention group
Group type: COMPARATOR
Intervention: Other early standard therapy (OEST, mainly methylphenidate)
Number of subjects: 398
Study 20946437 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (200 mg bi-hourly for 3 nights)
Number of subjects: 25
Study 20946437 — intervention group
Group type: COMPARATOR
Intervention: Placebo (indistinguishable gum bi-hourly for 3 nights)
Number of subjects: 25
Study 19438817 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin phosphate 1% with benzoyl peroxide 5% (CDP/BPO)
Number of subjects: 69
Study 19438817 — intervention group
Group type: COMPARATOR
Intervention: Adapalene 0.1% (ADA)
Number of subjects: 69
Study 17920770 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line treatments including certain antidepressants (tricyclic antidepressants and dual reuptake inhibitors of both serotonin and norepinephrine)
Number of subjects: 0
Study 17920770 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium channel alpha2-delta ligands (gabapentin and pregabalin)
Number of subjects: 0
Study 17920770 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical lidocaine
Number of subjects: 0
Study 17920770 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid analgesics and tramadol
Number of subjects: 0
Study 17920770 — intervention group
Group type: EXPERIMENTAL
Intervention: Certain antiepileptic and antidepressant medications, mexiletine, N-methyl-D-aspartate receptor antagonists, and topical capsaicin
Number of subjects: 0
Study 17920770 — intervention group
Group type: COMPARATOR
Intervention: No medications
Number of subjects: 0
Study 14717628 — intervention group
Group type: EXPERIMENTAL
Intervention: Angry opponent
Number of subjects: 0
Study 14717628 — intervention group
Group type: COMPARATOR
Intervention: Happy opponent
Number of subjects: 0
Study 14717628 — intervention group
Group type: EXPERIMENTAL
Intervention: Angry communications
Number of subjects: 0
Study 14717628 — intervention group
Group type: EXPERIMENTAL
Intervention: Large concessions by opponent
Number of subjects: 0
Study 12397467 — intervention group
Group type: EXPERIMENTAL
Intervention: (123)I-BZA(2) scintigraphy
Number of subjects: 25
Study 9661537 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-administered subcutaneous morphine
Number of subjects: 80
Study 9661537 — intervention group
Group type: COMPARATOR
Intervention: i.v. patient-controlled analgesia morphine
Number of subjects: 80
Study 2679231 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 to 10 degrees head-up tilt
Number of subjects: 100
Study 2679231 — intervention group
Group type: COMPARATOR
Intervention: Horizontal position
Number of subjects: 100
Study 2679231 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (head-up and horizontal)
Number of subjects: 100
Study 1146857 — intervention group
Group type: EXPERIMENTAL
Intervention: Directive play therapy
Number of subjects: 14
Study 1146857 — intervention group
Group type: EXPERIMENTAL
Intervention: Nondirective play therapy
Number of subjects: 14